Neuronal nicotinic receptor agonists for the treatment of attentioon-deficit/hyperactivity disorder: Focus on cognition

被引:116
作者
Wilens, Timothy E.
Decker, Michael W.
机构
[1] Massachusetts Gen Hosp, Pediat Psychopharmacol Res Unit, Yawkey Ctr Outpatient Care, Boston, MA 02114 USA
[2] Global Pharmaceut Res & Dev, Neurosci Drug Discovery, Dept R4N5, Abbott Pk, IL 60064 USA
关键词
ADHD; ABT-418; ABT-089; children; adolescents; cognitive deficits; treatment;
D O I
10.1016/j.bcp.2007.07.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Attention deficit/hyperactivity disorder (ADHD) is the most commonly diagnosed neurobehavioral disorder in children and adolescents, and in about half of these patients, significant symptomology continues into adulthood. Although impulsivity and hyperactivity are the most salient features of ADHD, cognitive deficits, particularly impairments in attention and executive function, are an important component, particularly in adolescents and adults, with over 90% of adults seeking treatment for ADHD manifesting cognitive dysfunction. Currently available medications treat the core ADHD symptoms but typically do not adequately address cognitive aspects of ADHD, underscoring the need for new therapeutics. Dopamine and norepinephrine are hypothesized to be particularly important in ADHD, but there is emerging evidence that cholinergic neurotransmission, particularly involving neuronal nicotinic acetylcholine receptors (nAChRs), may play a role in the pathophysiology of ADHD. Nicotine has demonstrated procognitive effects in both humans and experimental animals and has produced signals of efficacy in small proof-of-concept adult ADHD trials. Although adverse effects associated with nicotine preclude its development as a therapeutic, a number of novel nAChR agonists with improved safety/tolerability profiles have been discovered. Of these, ABT-418 and ABT-089 have both demonstrated signals of efficacy in adults with ADHD. Notably, tolerability issues that might be expected of a nAChR agonist, such as nausea and emesis, were not observed at efficacious doses of ABT-089. Further understanding of the effects of novel neuronal nAChR agonists on specific aspects of cognitive functioning in ADHD is required to assess the full potential of this approach. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:1212 / 1223
页数:12
相关论文
共 171 条
[1]   6-YEAR PREDICTORS OF PROBLEMS IN A NATIONAL SAMPLE OF CHILDREN AND YOUTH .1. CROSS-INFORMANT SYNDROMES [J].
ACHENBACH, TM ;
HOWELL, CT ;
MCCONAUGHY, SH ;
STANGER, C .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1995, 34 (03) :336-347
[2]   Molecular psychology: Roles for the ERK MAP kinase cascade in memory [J].
Adams, JP ;
Sweatt, JD .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2002, 42 :135-163
[3]  
[Anonymous], NEURONAL NICOTINIC R
[4]  
[Anonymous], 1989, International Pediatrics
[5]   POTENTIAL TREATMENT OF ALZHEIMER-DISEASE USING CHOLINERGIC CHANNEL ACTIVATORS (CHCAS) WITH COGNITIVE ENHANCEMENT, ANXIOLYTIC-LIKE, AND CYTOPROTECTIVE PROPERTIES [J].
ARNERIC, SP ;
SULLIVAN, JP ;
DECKER, MW ;
BRIONI, JD ;
BANNON, AW ;
BRIGGS, CA ;
DONNELLYROBERTS, D ;
RADEK, RJ ;
MARSH, KC ;
KYNCL, J ;
WILLIAMS, M ;
BUCCAFUSCO, JJ .
ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 1995, 9 :50-61
[6]  
Arneric SP, 1997, DRUG DEVELOP RES, V41, P31, DOI 10.1002/(SICI)1098-2299(199705)41:1<31::AID-DDR4>3.0.CO
[7]  
2-T
[8]  
ARNERIC SP, 1995, CNS DRUG REV, V1, P1
[9]   THE SPECIFICITY OF THE EFFECTS OF STIMULANT MEDICATION ON CLASSROOM LEARNING-RELATED MEASURES OF COGNITIVE PROCESSING FOR ATTENTION-DEFICIT DISORDER CHILDREN [J].
BALTHAZOR, MJ ;
WAGNER, RK ;
PELHAM, WE .
JOURNAL OF ABNORMAL CHILD PSYCHOLOGY, 1991, 19 (01) :35-52
[10]   REVIEW OF STIMULANT DRUG RESEARCH WITH HYPERACTIVE-CHILDREN [J].
BARKLEY, RA .
JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY, 1977, 18 (02) :137-165